期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 99, 期 1, 页码 60-69出版社
WILEY
DOI: 10.1111/ejh.12891
关键词
allogeneic transplantation; calreticuline; intent-to-treat analysis; JAK inhibitor; JAK2; myeloproliferative leukemia virus; primary myelofibrosis; secondary myelofibrosis
类别
ObjectiveThe role of allogenic stem cell transplantation (ASCT) is still debated in myelofibrosis (MF). MethodsA retrospective analyzed was performed to compare the outcome of 71 patients with intermediate-2 or high-risk Dynamic International Prognosis Scoring System+ (DIPSS+) primary (PMF) or secondary (SMF) myelofibrosis with an indication of ASCT as they ultimately underwent the procedure (n=34) or not (n=37). ResultsFive-year overall survival (OS) was not statistically different between both groups (allograft: 52% vs no allograft: 34%, P=.12). However, progression to myelodysplastic syndrome or acute myeloid leukemia at 5years was significantly lower in transplanted patients (14% vs 50%, P=.01). In univariate analysis, 5-year OS was significantly higher for transplanted vs non-transplanted patients with unfavorable karyotype (75% vs 0%, P=.001), SMF (71% vs 20%, P=.001) or high DIPSS+ score (46% vs 15%, P=.03). There was also a trend for better 5-year OS in allografted patients with high JAK2(V617F) burden (>65%) (75% vs 8%, P=.07). Interestingly, the survival of patients who did not proceed to ASCT was dramatically increased by the use of ruxolitinib. ConclusionsNot all intermediate-2/high-risk DIPSS+ MF patients benefit from ASCT, especially since the introduction of JAK2 inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据